---
title: "Mounjaro vs Wegovy: Which Is Right for You?"
date: 2026-06-11T13:22:00+01:00
author: Paulina Charlesworth
canonical_url: "https://drcharlesworth.co.uk/journal/mounjaro-vs-wegovy-which-is-right-for-you-in-sevenoaks"
section: Journal Articles
---
GLP-1 receptor agonists

## What Are Mounjaro and Wegovy?

Mounjaro (tirzepatide) and Wegovy (semaglutide) belong to a family of medicines called GLP-1 receptor agonists. These mimic natural gut hormones that help regulate appetite, digestion and blood sugar.

- **Wegovy (semaglutide):** Targets GLP-1 receptors.
- **Mounjaro (tirzepatide):** Targets both GLP-1 and GIP receptors, giving it a broader effect on metabolism and weight regulation.

**Reassurance:** GLP-1 medicines are not “brand new.” Ozempic (semaglutide for diabetes) has been used worldwide for over 20 years with a strong safety record. What’s new is their dedicated use for weight loss.

**Weight Loss Effectiveness**

- **Wegovy (STEP-1, NEJM 2021):** average 14.9% body weight loss over 68 weeks.
- **Mounjaro (SURMOUNT-1, NEJM 2022):** average 20.9% loss at highest dose over 72 weeks, with some >30%.

In practice: Both are highly effective, but Mounjaro often delivers faster, greater reductions, especially for patients with insulin resistance or higher starting weights.

Cardiovascular & Metabolic Benefits

- **Wegovy:** SELECT trial (2023) – reduced risk of heart attack, stroke, and CV death by 20% in adults with obesity (even without diabetes).
- **Mounjaro:** SURPASS-CVOT is ongoing; early signals suggest equal or greater protection, especially in type 2 diabetes.

Both also improve blood sugar, cholesterol, blood pressure and reduce systemic inflammation.

**Beyond Weight Loss: Everyday Health Benefits**

Clinical studies and real-world patient feedback show that GLP-1 medications can help with more than weight loss:

- Joint relief and mobility improvement
- Fertility and PCOS improvements
- Sleep apnoea (up to 60% reduction in severity in studies)
- Mood & focus, calmer, more in control, fewer ADHD-like symptoms
- Cost neutrality, savings on food, alcohol and snacks often offset much of the cost

I’ve written more about these *“ripple effects”* in my blog: [Mounjaro, Wegovy & ADHD: Beyond Weight Loss, Mood and Longevity](https://drcharlesworth.co.uk/journal/mounjaro-wegovy-adhd-beyond-weight-loss-mood-and-longevity)

**Cancer, Inflammation and Longevity Medicine**

Obesity is now recognised as the leading preventable cause of cancer in the UK, after smoking. Fat cells are highly pro-inflammatory, raising the risk of:

- Breast, bowel, pancreatic and liver cancers
- Heart disease, stroke, and dementia
- Osteoarthritis and other degenerative conditions

By reducing weight and inflammation (CRP, IL-6, TNF-α), Wegovy and Mounjaro don’t just change body shape — they may shift long-term cancer and disease risk.

**Why Rapid Weight Loss Carries Risks**

Any rapid weight loss, from medication, dieting, or surgery, can trigger risks:

- **Gallbladder issues (gallstones):** Rapid fat breakdown alters bile composition. Adults with obesity already face a 1–3% yearly risk; normal weight adults ~0.3–0.5%.
- **Pancreatitis:** Rare but serious inflammation of the pancreas. Risks were similar to placebo in trials.

These risks are linked more to the *speed* of weight loss than the medicine itself. That’s why I use a slow-and-steady approach with bespoke titration and micro-dosing if needed.

**Cost & Practicalities**

- **Wegovy:** £250–350/month depending on dose
- **Mounjaro:** £350–450/month (from September 2025)

**At my Sevenoaks clinic:**

- Direct dispensing (no middlemen, reliable stock)
- Unlimited GP consultations
- Bespoke dosing & micro-dosing available
- Free support prescriptions (e.g. anti-sickness) included if side effects occur

**Which Is Right for You?**

- **Wegovy:** best for patients seeking steady results, proven cardiovascular protection.
- **Mounjaro:** best for those needing more powerful results such as weight loss, especially with diabetes, fatty liver, or insulin resistance.
- **Either option:** works best within structured, doctor-led care that integrates lifestyle and nutrition.

**Licensing, Off-Label Use & Shared Decisions**

- Both are licensed for weight management under specific criteria.
- May also be prescribed *off-label* (e.g. micro-dosing or bespoke maintenance) after an individual risk–benefit discussion.

### Frequently Asked Questions

**Are these new medications?**  
Not entirely. Ozempic (semaglutide for diabetes) has been used safely for over 20 years.

**Do they cause cancer?**  
No. By reducing obesity and inflammation, they may lower long-term cancer risk.

**Can they replace diet and exercise?**  
No. They work best when combined with healthy lifestyle changes.

**Are all benefits licensed?**  
No. Some benefits (e.g. ADHD-like calm, reduced alcohol or smoking, longevity focus) are off-label observations.

### Final Thoughts

Wegovy and Mounjaro are extraordinary tools in modern weight loss medicine. They don’t just reduce weight — they can improve heart health, lower inflammation, reduce cancer risk, and support healthier habits for the long term.

**Off-label use warning:** Some benefits described are outside current UK licensing. At my clinic, we always have an open discussion of pros, cons, and alternatives before making a joint decision.